<code id='EBC8605A23'></code><style id='EBC8605A23'></style>
      • <acronym id='EBC8605A23'></acronym>
      <center id='EBC8605A23'><center id='EBC8605A23'><tfoot id='EBC8605A23'></tfoot></center><abbr id='EBC8605A23'><dir id='EBC8605A23'><tfoot id='EBC8605A23'></tfoot><noframes id='EBC8605A23'>
      • <optgroup id='EBC8605A23'><strike id='EBC8605A23'><sup id='EBC8605A23'></sup></strike><code id='EBC8605A23'></code></optgroup>
        5. <b id='EBC8605A23'><label id='EBC8605A23'><select id='EBC8605A23'><dt id='EBC8605A23'><span id='EBC8605A23'></span></dt></select></label></b><u id='EBC8605A23'></u>
          <i id='EBC8605A23'><strike id='EBC8605A23'><tt id='EBC8605A23'><pre id='EBC8605A23'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / knowledge / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-09-29 07:35:01 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：hotspot   
                                        
                                      
                                      Page View：339
                                  
                                    
          
                                   
          Martin Shkreli Securities Fraud Trial
          Kevin Hagen/Getty Images
          Is this the end of the line for the “pharma bro” with the perpetual smirk?
          Martin Skhreli was found guilty on Friday of three counts of fraud after a five-week trial in federal court in Brooklyn, N.Y. He faces a prison sentence that could stretch years.
          advertisement
          “This was a witch hunt of epic proportions,” Shkreli said outside court after the verdict, the Washington Post reported. “They may have found some broomsticks.”
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
                      
                              
          
                                 Previous article：

                                
                                          Roivant's CEO is a star, but biotech's black hole persists
                                
                            
          Next article：  
                                      
                                          Heart attack and stroke risk calculators need revising
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles